Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WASIM A HAQUE

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1679762405
CMS profile
75898
Location
FLOWER MOUND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,556.46

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,488.19 152
Education $68.27 2

By paying entity

PY2020 · entire year · sorted by reported total

Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WASIM A HAQUE

NPI 1679762405 · CMS profile ID 75898

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

FLOWER MOUND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679762405?year=2020&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WASIM A HAQUE, NPI 1679762405, CMS profile ID 75898. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679762405?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). WASIM A HAQUE, NPI 1679762405, CMS profile ID 75898. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679762405?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
WASIM A HAQUE, NPI 1679762405, CMS profile ID 75898, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679762405?year=2020&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $2,556.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–154 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mannkind Corporation $13.9501/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752671517 CMS
Abbott Laboratories $22.7501/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749020987 CMS
SANOFI-AVENTIS U.S. LLC $18.8401/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744151519 CMS
Lilly USA, LLC $17.7101/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728674673 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,947.45 195
PY2020 $2,556.46 154
PY2021 $2,764.11 156
PY2022 $7,564.90 107
PY2023 $1,733.87 75
PY2024 $3,451.79 125
PY2025 $3,030.09 141

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $752,600.89 18
PY2024 Recipient $35,134.00 1
PY2024 Principal investigator $1,170,638.49 42
PY2023 Recipient $3,266.17 2
PY2023 Principal investigator $447,130.77 17
PY2022 Recipient $4,088.00 1
PY2022 Principal investigator $134,044.68 35
PY2021 Principal investigator $26,769.95 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,150.00 10/10/2025 Non-covered Recipient Entity
Urgent Care Specialists Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068301
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,058.80 10/10/2025 Non-covered Recipient Entity
Urgent Care Specialists Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068303
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $18,351.00 10/10/2025 Non-covered Recipient Entity
Urgent Care Specialists Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068305
Principal investigator 1 Eli Lilly and Company $20,971.00 07/15/2025 Non-covered Recipient Entity
N TEXAS DIABETES AND ENDOCRINE
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187884294
Principal investigator 1 Medtronic, Inc. $3,750.00 05/23/2025 Non-covered Recipient Entity
Prime Revival Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327409
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,232.00 05/09/2025 Non-covered Recipient Entity
Urgent Care Specialists Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066399
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,226.00 03/21/2025 Non-covered Recipient Entity
Prime Revival Research Institute Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067435
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $30,184.00 03/21/2025 Non-covered Recipient Entity
Prime Revival Research Institute Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067437
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,520.00 02/26/2025 Non-covered Recipient Entity
Prime Revival Research Institute Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067793
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,092.00 02/26/2025 Non-covered Recipient Entity
Prime Revival Research Institute Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067795
Principal investigator 1 Acella Pharmaceuticals, LLC $117,934.40 02/07/2025 Non-covered Recipient Entity
Prime Revival Research Institute, LLC
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241767053
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2025 Non-covered Recipient Entity
N TEXAS DIABETES AND ENDOCRINE
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187885054
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
N TEXAS DIABETES AND ENDOCRINE
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187885634
Principal investigator 1 Eli Lilly and Company $1,258.39 01/31/2025 Non-covered Recipient Entity
N TEXAS DIABETES AND ENDOCRINE
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187885636
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $38,483.10 01/29/2025 Non-covered Recipient Entity
Prime Revival Research Institute Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066463
Principal investigator 1 Eli Lilly and Company $418,718.00 01/21/2025 Non-covered Recipient Entity
N TEXAS DIABETES AND ENDOCRINE
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187885632
Principal investigator 1 Eli Lilly and Company $46,135.00 01/21/2025 Non-covered Recipient Entity
N TEXAS DIABETES AND ENDOCRINE
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187886990
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $36,817.20 01/13/2025 Non-covered Recipient Entity
Prime Revival Research Institute Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066461